Olema Pharmaceuticals, Inc. (OLMA), Tuesday announced a new clinical trial collaboration and supply agreement with Pfizer Inc. (PFE) to evaluate in a Phase 1b/2 study the safety and combinability of palazestrant plus atirmociclib in metastatic breast cancer patients.
As per the terms of the agreement, Pfizer will supply atirmociclib for use in the Phase 1b/2 study and Olema will lead the conduct of the study.
If successful, the companies would proceed with a pivotal trial in the frontline setting.
CEO Sean Bohen of Olema commented, "With OPERA-01, our first pivotal study of palazestrant, underway and our OPERA-02 ribociclib combination trial in frontline metastatic breast cancer anticipated to initiate this quarter, we remain focused on achieving our goal of transforming the metastatic breast cancer treatment paradigm."
In the pre-market hours, Olema's stock is moving down 3.41 percent, to $5.25 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.